STOCK TITAN
  1. Home
  2. News
  3. VCYT

Veracyte, Inc. - VCYT STOCK NEWS

Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.

Veracyte, Inc. (symbol: VCYT) is a pioneering genomic diagnostics company dedicated to significantly enhancing patient care through innovative diagnostic solutions. The company specializes in developing and providing genomic diagnostic products and services that improve clinical outcomes by resolving the uncertainties inherent in traditional diagnostic methods.

Veracyte's core business revolves around creating tests that offer more accurate diagnoses without resorting to risky, costly, and often unnecessary surgeries. By employing top-tier scientific rigor, state-of-the-art tools, and the brightest minds in the field, Veracyte delivers diagnostic solutions that bring clarity and assurance to patients and physicians alike.

The company's product portfolio includes the Afirma analysis, Percepta, Envisia, and other cutting-edge diagnostic tests. These products are designed to tackle diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. Veracyte's diagnostic tests are distinguished by their ability to provide conclusive results where traditional methods fall short, thereby sparing patients from unnecessary surgical procedures.

Recent achievements highlight Veracyte's commitment to innovation and excellence. The company consistently introduces evidence that sets new standards in genomic tests, fundamentally altering current clinical practice norms. This commitment to scientific excellence ensures that Veracyte remains at the forefront of the genomic diagnostics industry.

Veracyte's impact extends beyond just clinical outcomes; it significantly influences the lives of both patients and physicians by offering a clearer path forward. Through continuous research, strategic partnerships, and an unwavering dedication to improving patient care, Veracyte stands out as a leader in the genomic diagnostics field.

News

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) reported strong financial results for Q4 and full year 2023, with total revenue growing to $98.2 million in Q4 and $361.1 million for the year. The company achieved a 22% increase in total revenue, driven by growth in test volume and revenue from their Afirma and Decipher businesses. Veracyte also highlighted key business achievements, including the acquisition of C2i Genomics Inc. and an agreement with Illumina. Despite a net loss for Q4 2023, the company remains optimistic about future growth and expects positive cash flow for the third consecutive year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.87%
Tags
earnings
-
News

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

Rhea-AI Summary
Veracyte, Inc. (VCYT) executives to present at Raymond James 45th Annual Institutional Investors Conference. Live webcast scheduled on March 4, 2024, at 9:50 a.m. Eastern Time. Replay available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
conferences
-
News

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) will release financial results for Q4 and full-year 2023 on February 22, 2024. A conference call and webcast will follow to discuss the results and provide a business update. The webcast replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
earnings
News

Veracyte Completes Acquisition of C2i Genomics

Rhea-AI Summary
Veracyte, Inc. (VCYT) has completed the acquisition of C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities to its diagnostics platform. The acquisition expands the company's ability to serve patients across the cancer care continuum, allowing them to deliver more value to clinicians and patients, beginning with early cancer diagnosis and risk assessment, and moving further along the patient journey into treatment monitoring and disease recurrence testing. Veracyte plans to develop further MRD tests in several of its focused indications. The transaction details include the acquisition of C2i Genomics for $70 million, paid for with 2.7 million Veracyte shares, with an additional $25 million payable based on the achievement of future performance milestones over the next two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
acquisition
-
News

Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform

Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) announces preliminary unaudited financial results for Q4 and full year 2023. Revenue expected to grow by 21%, reaching between $358 million and $359 million. Acquisition of C2i Genomics, Inc. broadens its presence across the cancer care continuum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.1%
Tags
acquisition earnings
-
News

Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) will be presenting at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024, at 1:30 p.m. Pacific Time. The CEO and CFO will be presenting, and a live webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.51%
Tags
conferences
News

Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

Rhea-AI Summary
Veracyte, Inc. (VCYT) announced new data presented at the 24th Annual Meeting of the Society of Urologic Oncology, highlighting clinical observations and translational research on the Decipher Prostate Genomic Classifier. The studies support its clinical utility in the treatment and management of prostate cancer, particularly for active surveillance candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
-
News

Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) has announced that its Percepta Nasal Swab test has been found to accurately determine lung cancer risk among current and former smokers with lung nodules, potentially avoiding unnecessary invasive procedures and accelerating appropriate treatment. The test is simple, non-invasive, and provides insights to objectively assess lung cancer risk, guiding physicians in determining which patients to work up for lung cancer and which to monitor with imaging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
-
News

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

Rhea-AI Summary
Veracyte, Inc. (VCYT) will present seven posters at the 24th Annual Meeting of the Society of Urologic Oncology, showcasing the clinical performance of its Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment. The posters will report data from over 60,000 patients, addressing the ongoing challenge in prostate cancer management. The company aims to provide a more complete understanding of each patient's cancer for personalized care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
none
News

Veracyte Announces Third Quarter 2023 Financial Results

Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) Grew Total Revenue to $90.1 million, an Increase of 19%
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.58%
Tags
earnings

FAQ

What is the current stock price of Veracyte (VCYT)?

The current stock price of Veracyte (VCYT) is $40.89 as of December 20, 2024.

What is the market cap of Veracyte (VCYT)?

The market cap of Veracyte (VCYT) is approximately 3.0B.

What does Veracyte, Inc. specialize in?

Veracyte, Inc. specializes in genomic diagnostics to improve patient care by resolving inconclusive results from traditional diagnostic methods.

What products does Veracyte offer?

Veracyte offers genomic diagnostic products such as Afirma, Percepta, and Envisia, targeting diseases like thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis.

How do Veracyte's tests improve clinical outcomes?

Veracyte's tests provide accurate diagnoses, reducing the need for risky and unnecessary surgeries by resolving ambiguity in traditional diagnostic methods.

What recent achievements has Veracyte accomplished?

Veracyte has consistently introduced evidence that sets new standards in genomic tests, changing today's clinical practice standards.

Who benefits from Veracyte's genomic diagnostic solutions?

Both patients and physicians benefit as Veracyte's tests offer clearer diagnostic paths, improving overall patient care and reducing unnecessary medical procedures.

In which diseases does Veracyte focus its diagnostic solutions?

Veracyte focuses on diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis.

What sets Veracyte apart from traditional diagnostic companies?

Veracyte leverages top-tier scientific rigor, advanced tools, and unmatched expertise to deliver unprecedented diagnostic accuracy without unnecessary surgeries.

How does Veracyte impact clinical practice standards?

Veracyte's innovative genomic tests provide evidence that fundamentally alters clinical practice standards, ensuring more accurate and less invasive diagnosis methods.

What is the significance of Veracyte's Afirma analysis?

The Afirma analysis is a key product in Veracyte's portfolio, offering accurate diagnosis for conditions like thyroid cancer, thus avoiding unnecessary surgeries.

Why is Veracyte considered a leader in genomic diagnostics?

Veracyte leads the industry due to its innovative solutions, consistent introduction of new evidence, and significant impact on improving patient care and clinical practices.

Stock VCYT logo
Veracyte, Inc.

Nasdaq:VCYT

VCYT Rankings

#1643 Ranked by Market Cap
N/A Ranked by Dividends

VCYT Stock Data

3.04B
76.88M
0.78%
104.58%
3.71%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
SOUTH SAN FRANCISCO